Logo image of ORIC

ORIC PHARMACEUTICALS INC (ORIC) Stock Fundamental Analysis

USA - NASDAQ:ORIC - US68622P1093 - Common Stock

10.71 USD
+0.15 (+1.42%)
Last: 9/22/2025, 11:22:00 AM
Fundamental Rating

3

Taking everything into account, ORIC scores 3 out of 10 in our fundamental rating. ORIC was compared to 538 industry peers in the Biotechnology industry. ORIC has a great financial health rating, but its profitability evaluates not so good. ORIC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ORIC has reported negative net income.
In the past year ORIC has reported a negative cash flow from operations.
ORIC had negative earnings in each of the past 5 years.
ORIC had a negative operating cash flow in each of the past 5 years.
ORIC Yearly Net Income VS EBIT VS OCF VS FCFORIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

ORIC's Return On Assets of -39.48% is in line compared to the rest of the industry. ORIC outperforms 59.85% of its industry peers.
Looking at the Return On Equity, with a value of -42.28%, ORIC is in the better half of the industry, outperforming 70.07% of the companies in the same industry.
Industry RankSector Rank
ROA -39.48%
ROE -42.28%
ROIC N/A
ROA(3y)-40.95%
ROA(5y)-34.77%
ROE(3y)-45.95%
ROE(5y)-38.42%
ROIC(3y)N/A
ROIC(5y)N/A
ORIC Yearly ROA, ROE, ROICORIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORIC Yearly Profit, Operating, Gross MarginsORIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ORIC has been increased compared to 1 year ago.
The number of shares outstanding for ORIC has been increased compared to 5 years ago.
There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORIC Yearly Shares OutstandingORIC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ORIC Yearly Total Debt VS Total AssetsORIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 23.73 indicates that ORIC is not in any danger for bankruptcy at the moment.
The Altman-Z score of ORIC (23.73) is better than 93.49% of its industry peers.
ORIC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.73
ROIC/WACCN/A
WACCN/A
ORIC Yearly LT Debt VS Equity VS FCFORIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 16.17 indicates that ORIC has no problem at all paying its short term obligations.
ORIC has a better Current ratio (16.17) than 91.08% of its industry peers.
ORIC has a Quick Ratio of 16.17. This indicates that ORIC is financially healthy and has no problem in meeting its short term obligations.
ORIC has a better Quick ratio (16.17) than 91.08% of its industry peers.
Industry RankSector Rank
Current Ratio 16.17
Quick Ratio 16.17
ORIC Yearly Current Assets VS Current LiabilitesORIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

ORIC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.00%.
EPS 1Y (TTM)-8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORIC will show a small growth in Earnings Per Share. The EPS will grow by 7.93% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.58%
EPS Next 2Y4.59%
EPS Next 3Y2.77%
EPS Next 5Y7.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORIC Yearly Revenue VS EstimatesORIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ORIC Yearly EPS VS EstimatesORIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORIC Price Earnings VS Forward Price EarningsORIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORIC Per share dataORIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.59%
EPS Next 3Y2.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORIC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (9/22/2025, 11:22:00 AM)

10.71

+0.15 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners98.51%
Inst Owner Change13.4%
Ins Owners1.63%
Ins Owner Change-0.55%
Market Cap1.04B
Analysts88.89
Price Target18.46 (72.36%)
Short Float %9.25%
Short Ratio8.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.71%
Min EPS beat(2)-4.01%
Max EPS beat(2)19.44%
EPS beat(4)2
Avg EPS beat(4)4.02%
Min EPS beat(4)-4.01%
Max EPS beat(4)19.44%
EPS beat(8)5
Avg EPS beat(8)4.21%
EPS beat(12)8
Avg EPS beat(12)3.73%
EPS beat(16)10
Avg EPS beat(16)4.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.63%
PT rev (3m)-2.16%
EPS NQ rev (1m)-1.04%
EPS NQ rev (3m)6.88%
EPS NY rev (1m)0%
EPS NY rev (3m)7.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 3.21
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.48%
ROE -42.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.95%
ROA(5y)-34.77%
ROE(3y)-45.95%
ROE(5y)-38.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.17
Quick Ratio 16.17
Altman-Z 23.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.72%
Cap/Depr(5y)115.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.44%
EPS Next Y4.58%
EPS Next 2Y4.59%
EPS Next 3Y2.77%
EPS Next 5Y7.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.76%
EBIT Next 3Y14.77%
EBIT Next 5YN/A
FCF growth 1Y-55.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.03%
OCF growth 3YN/A
OCF growth 5YN/A